Administration of the nitric oxide synthase (NOS) inhibitor, AP-nitro-L-arginine methyl ester (L-NAME) during pregnancy has been shown to compromise fetal growth. This study was designed to determine whether aminoguanidine, a predominate inhibitor of inducible NOS, affects fetal outcome. In addition, we extended the prenatal administration of L-NAME into the postnatal period (14 d) to determine whether neonatal growth and maturation were also affected. L-NAME, but not aminoguanidine, compromises fetal and placental growth. When compared with control 14-d-old pups, postnatal L-NAMEcompromised neonatal growth, whether it was given directly (intraperitoneally) (39.7 ± 1.1 versus 24.1 ± 1.0 g) or indirectly (38.6 ± 0.5 versus 22.2 ± 1.2 g) via maternal breast milk. Neonatal growth retardation was asymmetric, with brain sparing, suggesting a nutritional origin. L-NAME administration resulted in growth retardation that extended into adulthood, without evidence of catch-up growth. Treated neonates displayed the hallmarks of hypertrophic pyloric stenosis. Significant increases in stomach weight/pup weight (9.9 ± 0.3 versus 8.2 ± 0.4 X 10 3 ) and stomach volume/pup weight (12.0 ± 0.6 versus 9.4 ± 0.6 mL/100 g) with a concomitant Endogenous NO produced from L-arginine by NOS (1), is an important regulator in a number of physiologic proce sse s. Se veral different isoforms of NOS exist; the con stitutive isoforms regul ate v ascular tone (1), neurotransmission (2), and platelet aggregation (3), w hereas the ind ucible for m appears to have its primary effect s on inflammation (4, 5) and host defense (6). A number of exog enous NOS inhibitors have been identified including the structural an alog of L-arginine, I.-NA ME, w hich inhibits both co nstitutive and inducible NOS isoforms , wi th pr eference for the constitut ive isoform (7, 8 Supported in parI by National Institutes of Health Granl ROI HD31885 (to MJ.S.M.) and American Heart Association, Louisiana Chapter (to M.R.P.). decrease in small intestine weight/length (2.10 ± 0.08 versus 3.18 ± 0.13 g/100 em) was noted in treated versus control pups (p < 0.05). Muscularis hypertrophy at the pyloric sphincter in the L-NAME-treated pups was noted by histology. Blood pressure was elevated in the L-NAME-treated pups (93 ± 6 versus 60 ± 5 mm Hg in control pups, p < 0.05). These findings are consistent with inhibition of neuronal and endothelial NOS activity. We conclude that NO, formed via the constitutive isoforms of NOS, is a critical determinant of fetal and neonatal growth and maturation. (Pediatr Res 38: 768-774, 1995) Abbreviations NO, nitric oxide NOS, nitric oxide synthase cNOS, constitutive nitric oxide synthase iNOS, inducible nitric oxide synthase L-NAME, AP-nitro-L-arginine methyl ester HPS , hypertrophic pyloric stenosis VIP , vasoactive intestinal polypeptide nidine, although not a i-arginine anal og, predominately inhibits the indu cible NOS isoform (9) .
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NO fo rma tion is up-regul ated in pregn ancy (10) . Th e uteroplacental unit via both co nst itutive and inducible pathways appea rs to form NO und er these co nd itions (11, 12) . We recently reported that earl y third trimest er (gestation al d [13] [14] [15] [16] [17] [18] [19] NOS inhibition with I.-NA ME in rats, alth ough not affecting indices of maternal health, resulted in mark ed fetal and placent al grow th retardation (13) . To bett er address the path oge nesis of the intraut er ine growth re tardation observed wi th third trimester NOS inhibition , the present studies were designed to determine w het her the timing and duration of pren atal NOS inhibitio n affects the degree of gr owth retardation observed and whether prenatal NOS inhibition w ith the predominatel y inducible NOS inhibitor, aminogua nidine, wo uld alter int raut erin e growth. In addi tion, as there are no rep orts on NO AND HYPERTROPHIC PYLORI C STENOSIS 769 the role of NO on neonatal growth and maturation , we extended the prenatal administration of L-NAME into the postnatal period (i.e. perinatal).
METHODS

Prenatal Studies
Chronic second and late third trimester NOS inhibition with L-NAME. Timed pregnant rats (Holtzman, Harlan Sprague-Dawley) were obtained on gestational d 6 of a 22-d gestation. They were randomly assigned to one of three treatment groups: the first received the NOS inhibitor, L-NAME (Sigma Chemical Co., St. Louis, MO) at 0.3 or 1.0 mg/mL in the drinking water, for 14 prenatal days (gestational d [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Based on water consumpti on these doses of L-NAME approximate to 55 and 180 mg/kg/day, respectively. The second group received L-NAME (same doses) for 4 prenatal days (gestational d [16] [17] [18] [19] . The third group was a water only control. Daily fluid consumpti on was followed per cage of two to three animals that were uniformly treated, to estimate daily dosage. The dose range used in this study encompassed doses known to reduce the elevated NO production associated with experimental inflammatory bowel disease (5, 14) and elicit hypertension in adult animals (14) (15) (16) . This oral route of administr ation has been routin ely used by ourselves (5) and others (15, 16) and is a simple and reliable approach to the chronic administration of NOS inhibitors.
On gestational d 20, dams were killed by an overdose of intramuscular ketamin e:xylazine anesthesia (Ketalar, ParkeDavis, Morris Plains, NJ, and Rompun , Paynet Cutter Labs, Shawnee, KS). Uterine horns were removed in block. Fetuses and placentas were removed from the uterus and weighed. Fetuses were eutheniz ed with an overdose of ketamine and xylazine.
Aminoguanidine studies. Timed pregnant rats were obtained in the third trimester (gestation al d 13) [timing based on the above results and our earlier study (13) ]. They were randomly assigned to one of two treatment groups; the first received aminoguanidine (Sigma Chemical Co.), a prototypical iNOS inhibitor, at 1.0 mg/mL for 7 prenatal days (gestational d [13] [14] [15] [16] [17] [18] [19] , which approximates to 180 mg/kg/d in the drinking water. The dose of aminoguanidine used has been shown by us (17) and others to inhibit iNOS (14, 18, 19) . The second group was a water-only control. On gestational d 20, dams were killed, and fetuses and placentas were removed and weighed.
Perinatal Studies
Postnatal growth. Timed pregnant rats were obtained on gestational d 6 and randomly assigned to one of two main groups, A and B (Fig. 1) . Group A consisted of dams receiving L-NAME (1.0 mg/mL) for either 7 or 14 prenatal days, in the drinking water. Group B consisted of dams not receiving prenatal treatment. After a normal parturition, newborns in group A were subdivided into those receiving 14 postnatal days of either L-NAME (1.0 mg/mL of maternal drinking water, i.e. through maternal breast milk) or water only. Newborns in group B were subdivided into those receiving 14 postnatal days PRENATAL NORMAL PARTURITION-------- Figure 1 . Perinatal grow th treatment scheme. Group A received L-NA ME (1.0 mg/mL) for either 7 or 14 prenatal days, in the drinking water immediately before a normal parturition. Postnatal L-NAME was administered either indirectly in maternal breast milk (po) or directly by intraperitoneal (ip) injections.
POSTNATAL
of either L-NAME or water. For group B L-NAME was administered either indirectly via maternal breast milk (1.0 mg/mL of maternal drinking water), or directly by intraperitoneal injections (as described below). Intraperitoneal L-NAME was given to ensure that findings were not seco ndary to maternal factors. L-NAME (180 mg/kg) in 0.1 mL of water was injected daily for 14 postnatal days; controls received an equal volume of water. After this 2-wk treatment period, control and L-NAME groups were handled in a similar manner; nursing was continued until weaning. Growth was monitored for 6 postnatal months . Once noting a remarkable delay in postnatal growth at 14 d of life with L-NAME, we explored a variety of parameters in an attempt to understand the pathogenesis involved.
Postnatal growth retardation. All of the pups receiving L-NAME treatments (pre-or postnatal only, or pre-and postnatal) were significantly smaller then their control counterparts at 14 d of age (see Fig. 3 ). The greatest effects on neonatal growth were noted with 14 d of postnatal L-NAME treatment (Fig. 3, C-F) , as opposed to only prenatal L-NAME administration (Fig. 3, A and B) (p < 0.05). In addition, growth rates were not influenced by postnatal mode of delivery (i.e. per os versus intraperitoneally; Fig. 3 , C, E, and F , versus D) or combined prenatal plus postnatal (Fig. 3, E and F) versus postnatal L-NAME only (Fig. 3, C and D 
A clinical hallmark of hypertrophic pyloric stenosis is vomiting. Although rats do not vomit it was readily noticeable that the abdomens of L-NAME-treated pups were grossly enlarged. Subsequently, indices of hypertrophic pyloric stenosis wer e evaluated in a different group of animals. Because pups receiving prenatal plus postnatal L-NAME were most significantly affected, this protocol was adopted, and L-NAME administration was extended to 21 postnatal days. In addition , as growth retardation and gastric distension were not influenced by mode of delivery (i.e. per os versus intraperitoneall y), due to ease of administration postnatal L-NAM E was administered through maternal breast milk (per os).
On the 14th or 21st postnatal day after an overdose of ketamine:xylazine, an intracardiac puncture was done to collect 1-2 mL of blood for analyses (see below). A midline incision was made, and the abdominal and pulmonary cavities were exposed. Stomachs were inflated through an esophageal catheter with normal saline (20 em H 2 0 pressure). The volume . The * depicts a significant difference in the L-NAME groups compared with water controls (p < 0.05). The @ depicts a significant difference (p < 0.05) between L-NA ME 0.3 mglmL vs L-NAME 1.0 mglmL treatment groups for each prenatal treatment day. The # depicts a significant difference (p < 0.05) between treatment days for each L-NAME dose. Table 1 .
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Maternal intake and weight gain
Values are mean::!: SE M. L-NAME 0.3 mg/ml, (4 d) = 6 dams, L-NAME 1.0 mglm L (4 d) = 6 dams, L-NAME 0.3 mglmL (14 d) = 4 dams, L-NAME 1.0 mglmL (14 d) = 4 dams, and control = 8 dams. Postnatal growth. In rats exposed to L-NAME only prenatally , postna tal growth rema ined significantly retarded on the 14th d of life, despite discon tinuation of L-NAME at birth (Fig.   3 , A and B, p < 0.05) when compared with control groups (Fig.   3, G and H) . Postnatal treatm ent with L-NAME resulted in Chronic second and late third trimester NOS inhibitio n with L-NAME. The presenc e of L-NA ME did not influence drinkin g or feeding beha vior as both were consumed at comparable quantiti es, regardless of dose or duration of administration (Table 1) . Maternal weight gain was also comp arable, regardless of dose or durati on of admini stration .
Fetal growth was retard ed in a dose-(0.3 versus 1.0 mglmL) and time-dependent fashion by L-NAME administrat ion; evident with 4 d (gestation al d [16] [17] [18] [19] Fig. 2 ; p < 0.05). Consistent with the reducti ons in pup from the esophageal-abdominal inlet to the pyloric outlet was measured. Protein content of the stomach was measured with a Bio-Rad protein assay kit (Richmond CA), using a Bio-Rad mod el 3550 enzyme-immunoassay reader. Protein standard was prep ared with lyophilized bovine -y-globulin. Sections of stomach were weighed and then placed in a desiccator for 72 h to obtain dry weights. In a subset of animals the pyloric sphincter was removed and prepared for standard histologic evaluation (hematoxylin and eosin). The small intestine from the duodenum to the ileo-ceca l valve was removed , cleansed of fecal material, measured, weighed, and then placed in a desiccator to obtain dry weights. In addition, fetal kidneys, brain , and liver were also remov ed and weigh ed.
Blood pressure eleva tion is a hallmark of cNOS inhibition and was examined on postnatal d 21 (attempted on postn atal d 14, but was not technically feasible in a reliab le manner). A subgroup of newborns were anesthetized with intramuscul ar ketamine:xylazine anesthe sia (40 mglkg:4 mg/kg) to maintain anesthesia, as determined by corne al reflexes. The internal carotid artery was exteriorized, cannu lated (PElO), and connected to a Gould pressure transduc er (model P3800 , GouldStatham, Oxnard, CA) for continuous measurements of mean arterial blood pressure. Calibrations of pressure transduc ers were done with a mercury manometer. After a post surgical stabilization period resulting in a stable baseline mean arterial blood pressure measurement, the blood pressure was monitored for a IS -min period. The newborns were killed by exsanguination via the carotid cannulation. Hearts were removed and weighed after 14 and 21 d of life.
To explore infectious and inflammatory components for the delayed postnatal growth , blood was evaluated for hematocrit and white blood cell numb er. Circulating leukocyte levels were manu ally quantified. Cardiac blood was collected and mixed with 9 volumes of 3% acetic acid (1 :10 dilution). The Neubauer chamber was charg ed with a drop of the blood mixture, and white cells were counted with light micr oscopy. In addition, myeloperoxidase activit y was determined in the ileum as previousl y described (5) .
Statistical analysis. To compare biochemical values and weights for different treatments, one-way analysis of variance was done followed by Dunc an 's multipl e range test (20 
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Figure S. Indices of hypertrophic pyloric stenosis. Stom ach weight/pup weight (ST WFIPUP W7)( X 10 3 ) , stomach volume/pup weight (ST VOU PUP W7)(mL/100 g of pup weight), small intestine weight/small intestine length (S f WFISf L7)(g/100 cm of small intestine) in pups receiving 7 prenatal and 14 or 21 postnatal days of L-NAME, compared with control 14-and 21-d -old pups. The columns represent the mean ::' :: SEM. The • depicts a significant difference in the L-NAME groups compared with water controls (p < 0.05; n = 4 litters/group ; 10-12 pups/litter). ± 0.18 and 4.99 ± 0.19, respec tively). Toget her these findings are consistent with hypertrophy of the gastric musculature secondary to an obstruction of its outlet with a secondary atrophy of the small intestine, i.e. hypertrophic pyloric stenosis. Histologic evaluation of the pyloric sphincter revealed muscularis hypertrophy and hyperplasia of the circular muscle of the muscularis propria of the pylorus after 14 or 21 d of postnatal L-NAME when compared with pyloric sphincters of 14-or 21-wk-old control pups (Fig. 6) .
Growth retardation was asymmetric, consistent with a nutritional deficit. Brain weight/body weights in L-NAME treated 14-and 21-d-old pups were significantly increased when compared with control counterparts (Table 2 ) and are consistent Figure 4 . Pup weight (grams) after the specified prenatal and postnatal treatments with oral (po, maternal breast milk) (1.0 mg/mL , -180 mg/kg/d) L-NAME at 1-6 mo of age. A = Control, zero prenatal or postnatal treatments with L-NAME. B = 7 prenatal days of oral L-NAME and no postnatal treatments. C = 7 prenatal days of L-NAME and 14 postnatal days of oral L-NAME. D = zero prenatal days of L-NAME and 14 postnatal days of oral L-NAME. The columns represent the mean weight in grams for 1-6 mo of age. The • depicts a significant difference in the L-NAME groups compared with water control at each month (p < 0.05; n = 4 litters/group; 10-12 pups/litter). growth retardation at 14 d of life, whether administering it orally via maternal breast milk (Fig. 3C) or by intraperitoneal injection (Fig. 3D) and regardless of whether prenatal L-NAME was administered (Fig. 3, E and F) or not (Fig. 3, C and D) whe n compared with control groups (Fig. 3, G and H) . L-NAME-treated pups also had a delay in the time it took to open their eyes, an index of their maturational retardation . On d 14 only 19% of L-NAME-treated pups had their eyes open, compared with 82% of control pups. When grow th was followe d for 6 mo of life there was no evidence of "catch-up" grow th (Fig. 4) .
Postnatal growth retardation . Althou gh the L-NAMEtreated newborns were significantly smaller than their water control counterparts, their stomachs were noticeably enlarged and engorged with food. We established a series of tests to determine whether these observations were due to HPS. There was a significant increase in stomach weight/pup weight, stomach volume/pup weight , concom itant with a decrease in small intestine weight/length (thickness) in the pups receiving 7 prenatal and 14 or 21 postnatal days of L-NAME compared with control pups (Fig. 5) . In addition, gastric wall protein content was increase d in 14-and 21-d-old L-NAME treated pups (3141 ± 258 and 442 1 ± 221 j.Lglg, respectively) compared with their control counterparts (2001 ± 235 and 3100 ± 210 j.Lglg, respectively) (p < 0.05). Stomach edema was not present as assessed by comparative wet-to-dry weights in L-NAME-treated 14-and 21-d-old pups (5.13 ± 0.32 and 5.04 ± 0.19, respectively) compared with control counterparts (4.83 Figure 3 . Neonatal weights in grams on the 14th day of life after the specified prenatal and postnatal days of either oral ( po, maternal breast milk) (1.0 mg/mL,~180 mg/kg/d) or intraperitoneal (ip , 180 mg/kg/d) L-NAME. A = 7 prenatal days of oral L-NAME and zero postnatal treatments. B = 14 prenatal days of oral L-NAME and zero postnatal treatments. C = zero prenatal days of L-NAME and 14 postnatal days of oral L-NAME. D = zero prenatal days of L-NAME and 14 postnatal days of intraperitoneal L-NAME. E = 7 prenatal days of oral L-NAME and 14 postnatal days of oral L-NAME. F = 14 prenatal days of oral L-NAME and 14 postnatal days of oral L-NAME. G = zero prenatal days of L-NAME and intraperitoneal injec tions of water for 14 postnatal days. H = zero prenatal and postnatal days of L-NAME. The columns represent the mean ::' :: SEM. The • depicts a significant difference in the L-NAME groups compared with water (po or ip) controls (p < 0.05; n = 6-8 litters/group). The # depicts a significant difference in the L-NAME postnatal treatment groups compared with the L-NAME prenatal only treatment groups (p < 0.05; n = 6 litters/group ; 10-12 pups/litter). with asymmetric growt h secondary to malnutrition anticipated in hypertrophic pyloric stenosis.
Systemic mean arterial blood pressure at 21 d was increased in the L-NAME-treat ed newborns compared with untreated controls (Table 2) . Heart weight/pup weig hts were not significantly different between groups. Hemato crits were not significantly different. Kidne y and liver weights/body weight were similar in all groups ( Table 2) .
All markers of an infectio us or inflammatory process including white blood counts and intestinal myeloperoxidase were similar in all study groups (Table 2) .
DISCUSSIO N
NO formation is up-regulated in pregnancy (10). Both constitutive and induc ible pathwa ys appear to contrib ute to NO production in the utero-placental unit. Studies of the role of NO in the fetus and newborn have been limited; primarily focusing on its role in the pulmonary circulation . We have recentl y shown that administration of the predomin ately eNOS inhibitor, L-NAME, throughout the last third of pregnancy results in reduction of fetal and placen tal growth (13) . To better address the pathophysiologic mechanism responsible for these findings, we undertook a series of experimental studies designed to determine to what degree the gestational timing of NOS inhibitor administration would alter fetal growth , whether inadequate NO production through inhibition of the iNOS isoforms would alter fetal growth and whether NOS inhibition during the neonatal period would also effect neonatal growth and maturation .
L-NAME predominately inhibits activity of the cNOS isoforms, whereas aminoguanidine predominately inhibits the activity of the iNOS isoforms . After prenata l L-NAME, fetal and placental growth was reduced in a dose-and timedependent fashi on (Fig. 2) . Amin oguanidin e did not alter intrauterine growth , and the purpose of a sustained expressi on of iNOS in pregnancy remains to be determined. In addition, matern al health was not compromised (data not shown). These findings suggest that growth retardation induced by L-NAME was most likely due to inhibition of eNOS. As placental growth was also compromised, inhibition of endothelial-derived NO may compromise placental function, limiting the maternal-fetal exchange of oxygen, nutrients , and metabolic wastes. This propos al agrees with work demons trating that both NOS inhibition (21) and inhibition of NO-activated guanylate cyclase (22) augments umbilical-placental vascular tone, whereas umbilical blood flow decrease s. Studies demonstrating that intracellular generation of NO by both glyceryltrinitra te and Snitro-N-ace tylpeni cilla mine vas odilates the feta l-placental circ ulation preconstricted with the thromboxane mimet ic U46619 (22) . Collectively our study and those cited sugges t that constitutive release of NO, througho ut pregnancy, regulates resting umbilical -placental vascul ar resistance and placental growt h, and impacts greatly on fetal well being.
Postnatal treatment with L-NAME resulted in postnatal grow th retardation that was significantly more dramatic than prenata l administration (Fig . 3, C-F, versus A and B, respectively). This growth retard ation was asymmetric , with brain sparing (Table 1) , suggesting a nutrition al origin . L-NAME was effective in the neonate whether it was administered orally to the mother and therefore reached the newborn via maternal breast milk (Fig. 3, C, E, and F) or by direct intraperitoneal injection to the newborn (Fig. 3D) and regardless of whether prenatal L-NAME was administered (Fig. 3, A and B) or not (Fig. 3, C and D) . L-NAME was directl y admini stered to the neonates by the intraperitone al route to discount the possible influence of maternal factors and to assure optimal delivery of L-NAME to the neonates. The present results are the first to suggest that L-NAME is secreted in an active form in breast milk.
The 14-d-old L-NAME-t reated pups, although visibly smaller than their control counterp arts, had stomachs that appeared disproportionally enlarged and engorged with food, whereas their intestines appeared thin and friable. HPS is a common disorder of the gastrointestinal tract in human infants. It is characterized by gastric-outlet obstruction associated with hypertrophy, hyperplasia, or both, of the circu lar musculature of the pylorus secondary to failure to relax. Although it has been recogni zed as a disease entity for more than two centuri es (23) , its physiopathologic mechanism is not known . Recentl y a genet ic knockout strains of mice devoid of the neuronal isoform of eNOS has been described. Surprisingly, these animals displayed little pathology, except marked HPS (24) .
Neurona l NOS is distributed throughout the myenteric plexus in the rat gut from stomach to distal colon (25), acting Heart/pup wt, ( X lO as an import ant mediator of relaxation of the esophagus (26), stomach (27) , intestine (28) , colon (29) , and pylorus (30). The excitatory inner vation of the pylorus is largely cholinergic from the vaga l nerve (31) . Inhibitory innervation, producing relaxation of the pyloric smooth muscle, is thought to be secondary to non-adrenergic non-cholin ergic neurotransmitters such as vaso active intestinal polypeptide (32) . However, incompl ete block ade of non-adrenergic non-cholinergic neurotransmitt er-mediated relaxation by VIP antiseru m suggests that a non-VIP component is also involved in producing relaxation of the pyloru s (33) . NO has recently been shown to act synergistically with VIP to cause vasorelaxation, whereas L-NAME decreases inhibitory jun ction potentials in the pyloric canal (30). It has also recently been shown that pyloric tissues from infants with HPS have enteric nerve fibers enlarged and distorted and do not contain NOS activity (34) that is normally present in nerve fibers of the pyloric musculature. Our studies and those cited suggest that lack of NOS in enteric nerves of the smooth musculature of the pylorus sphincter may account for the defect in relaxation of the pyloric sphincter in infantile HPS and that NO may be the non-VIP component responsible for relaxation of the pylorus. In our study, exposure to the cNOS (neuronal) inhibitor, L-NAME , in the neonatal period links neuronal NOS to HPS and affirms the role of NO in newborn gastric function . The stomach was hypertrophied, whereas the small intestine was atrophied, suggesting an obstruction of nutrient delivery from the stomach to the intestine. Malnutrition was so severe as to cause mark ed growth retardation with classic sparing of the brain over viscera. Although it remains to be demonstrated, this study raises the possibilit y that NO donors may be an effective medical treatment of pyloric stenosis and other forms of pylorospasm. Although a nonsurg ical approach for this cond ition would be welcome, potential systemic complications (hypotension , inhibition of platelet aggreg ation) would need to be judiciously evaluated and limited .
In conclusion the fetal complications appear to result from compromised placental grow th, consistent with inhibition of endothelial NOS activity. The neonatal complications predominately result from malnutr ition secondary to hypertrophic pyloric stenosis and hypertension, consistent with inhibition of neuronal and endothelial NOS activity, respectively. Synthesis of NO from i-a rginine by a constitutive NOS isoform is essential for fetal and neonatal grow th and development.
